EDAP to Present Prostate Cancer Data At American Urological Association Annual Meeting

High Intensity Focused Ultrasound Offers a Potentially Effective, Minimally Invasive Alternative to Existing Prostate Cancer Therapies

LYON, France, Apr 22, 2009 (GlobeNewswire via COMTEX News Network) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that five presentations on European and Canadian study results looking at the use of High Intensity Focused Ultrasound (HIFU) for the treatment of localized prostate cancer will be presented at the American Urological Association (AUA) Annual Meeting, to be held in Chicago, IL, April 25-30, 2009. The presentations are:

- Primary Prostate HIFU without Pretreatment Hormone Therapy: Biochemical Survival of 468 Patients Tracked with the @-Registry will be presented by Dr. Andreas Blana from the University of Regensburg, Germany on Sunday April 26th at 5:10pm.
- Correlation of Biochemical Events and Clinical Failure Following High Intensity Focused Ultrasound of the Prostate: The Stuttgart Definition, will be presented by Dr. John Ward of MD Anderson Cancer Center in Houston on Sunday April 26th at 5:00pm.
- 3-Year Biochemical Failure-Free Rate Following HIFU for Localized Prostate Cancer: Prospective Cohort Single Center Study of 265 Patients will be presented by Dr. William Orovan of McMaster University in Canada between 10:30am and 12:30pm on Wednesday April 29th.
- Outcomes of Salvage HIFU for recurrent prostate cancer following failed radiation therapy will be presented by Dr. Pinthus from the Cote de Nacre University Hospital, Caen, France, between 10:30 am and 12:30 pm on Wednesday April 29th.
- Evaluation of the risk reward ratio of a repeat HIFU procedure for residual prostate cancer by Dr. Pinthus from the Cote de Nacre University Hospital, Caen, France between 10:30 am and 12:30 pm on Wednesday April 29th.

Meeting attendees can learn more about HIFU technology and view a demonstration of EDAP's Ablatherm-HIFU device at booth #3612.

Marc Oczachowski, EDAP's Chief Executive Officer, said, "We are pleased to present new data which support the safety and efficacy of HIFU presented at AUA. As HIFU adoption continues to gain momentum in Europe, we look forward to expanding awareness in the United States of the potential of HIFU as a minimally invasive alternative to existing therapies to preserve patient quality of life."

About EDAP TMS SA

EDAP TMS SA develops and markets Ablatherm, the most advanced and clinically proven choice for high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. Approved in Europe as a treatment for prostate cancer, Ablatherm-HIFU (High Intensity Focused Ultrasound) is currently undergoing evaluation in a multicenter U.S. Phase II/III clinical trial under an Investigational Device Exemption granted by the FDA, the ENLIGHT US clinical Study. The Company also is developing this technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and commercializes medical equipment for treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the company, please visit http://www.edap-tms.com, http://www.hifu-planet.com and http://www.pcaresearch.com.

Forward-Looking Statements

In addition to historical information, this press release contains forward-looking statements that involve risks and uncertainties. These include statements regarding the company's growth and expansion plans. Such statements are based on management's current expectations and are subject to a number of uncertainties and risks that could cause actual results to differ materially from those described in these forward-looking statements. Factors that may cause such a difference include, but are not limited to, those described in the company's filings with the Securities and Exchange Commission. Ablatherm-HIFU treatment is in clinical trials, but not FDA-approved or marketed in the United States.

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: EDAP TMS S.A.

EDAP TMS SA
Investor Relations / Legal Affairs
Blandine Confort
+33 4 72 15 31 72
bconfort@edap-tms.com

The Ruth Group
Investors:
R.J. Pellegrino
646-536-7009
rpellegrino@theruthgroup.com

News Provided by COMTEX